Does earlier HIV RNA suppression provide long-term benefits?

AIDS

Volumn 24, Issue 10, 2010, Pages 1591-1593

  Moyle, Graeme ^a   Demasi, Ralph ^b   Hill, Andrew ^c  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^b Tibotec Research and Development   (United States)

^c UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ATAZANAVIR PLUS RITONAVIR; DARUNAVIR PLUS RITONAVIR; EFAVIRENZ; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; RALTEGRAVIR; VIRUS RNA;

ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG EFFICACY; GENE REPRESSION; GENETIC CORRELATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL; REBOUND;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CLINICAL TRIALS, PHASE III AS TOPIC; HIV INFECTIONS; HIV-1; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RNA, VIRAL;

EID: 77953913260     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32833ad933     Document Type: Article

References (7)

1. Riddler S, Haubrich R, DiRienzo A, Peeples L, Powderly WG, Klingman KL, et al., ACTG Study 5142 Team. Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med 2008; 358:2095-2106.
2. R patients [abstract #H924b]. In: 49th ICAAC; 12-15 September 2009; San Francisco, California, USA.
3. Johnson M, Soriano V, Brockmeyer N, Winston A, Gellermann H, Cairns V, De Rossi L. Early virological and immunological response is comparable between nevirapine and RTV-boosted atazanavir: an ARTEN sub-analysis [abstract #H-924c]. In: 49th ICAAC; 12-15 September 2009; San Francisco, California, USA.
4. Ebrahimi R, Pearce G, Chen S, Warren D. Time to viroligic response if not associated with response durability in treat-ment-naïve patients receiving efavirenz-based highly active antiretroviral therapy [abstract #BPD/7]. 12th European Conference; November 2009; Cologne, Germany.
5. Mills A, Cotte L, Smith S, Hill A, Peeters M, Vingerhouts J, De Smedt. Durability of virologic response to etravirine is not affected by time to reach virologic response [abstract #H-1238]. 48th Interscience Conference on Antimicrobial Agents and Chemotherapy; October 2008; Washington, District of Columbia, USA.
6. Mills A, Nelson M, Jayaweera D, Ruxrungtham K, Cassetti I, Girard P, et al. Once-daily darunavir/ritonavir vs lopinavir/ritonavir in treatment-näive, HIV-1 infected patients: 96-week analysis. AIDS 2009; 23:1679-1688.
7. Banhegyi D, Katlama C, Da Cunha C, Schneider S, Rachlis A, Romanenko O, et al. Phase III TITAN week 96 final analysis: efficacy/safety of darunavir/r (DRV/r) vs. lopinavir/r (LPV/r) in LPV-näive, treatment-experienced patients. Ninth International Congress on Drug Therapy in HIV Infection. Glasgow, UK. 9-13 November 2008. J Int AIDS Soc 2008; 11 (Suppl 1):22.